Zobrazeno 1 - 10
of 128
pro vyhledávání: '"P.P. Bapsy"'
Publikováno v:
South Asian Journal of Cancer, Vol 11, Iss 03, Pp 207-212 (2022)
Abstract Pravesh Dhiman, DNB (Medical Oncology). Background Epithelial ovarian cancer (EOC) is one of the leading causes of cancer-related death in women. Approximately 70% of patients with EOC are diagnosed in advanced stage [The International Fed
Externí odkaz:
https://doaj.org/article/f19e69444c994f008ab0acff9b1e3e0e
Publikováno v:
South Asian journal of cancer. 11(3)
Background Epithelial ovarian cancer (EOC) is one of the leading causes of cancer-related death in women. Approximately 70% of patients with EOC are diagnosed in advanced stage [The International Federation of Gynecology and Obstetrics(FIGO stage III
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b9b841160b928f7e7865c90ab23f940
https://pubmed.ncbi.nlm.nih.gov/36588609
https://pubmed.ncbi.nlm.nih.gov/36588609
Autor:
Sakshi Kohli, Venkata Sathya Suresh Attili, Ashok K. Vaid, P.P. Bapsy, Bandana Sharan, Minish Mahendra Jain, Chaitanya Kumar, Jagan Mohan, Srikanth Chiliveru
Publikováno v:
Immunotherapy. 9:889-897
Aim: A retrospective survival benefit analysis of APCEDEN®, APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7663f221f62b538eab93094c7f57db6
https://doi.org/10.2217/imt-2017-0064
https://doi.org/10.2217/imt-2017-0064
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P.P. Bapsy, Bandana Sharan, Ashok K. Vaid, Minish Mahendra Jain, Sakshi Kohli, Chaitanya Kumar, Venkata Sathya Suresh Attili
Publikováno v:
Journal of biosciences. 42(1)
The interplay between host immunity and tumour cells has opened the possibility of targeting tumour cells by modulation of the human immune system. Cancer immunotherapy involves the treatment of a tumour by utilizing the recombinant human immune syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb23a32348a9dec4d258620ef431cbf9
https://pubmed.ncbi.nlm.nih.gov/28229976
https://pubmed.ncbi.nlm.nih.gov/28229976
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer
Autor:
Lokanatha Dasappa, Raghunadharao Digumarti, Attili V. Suresh, David E. Gerber, Joseph Shan, P.P. Bapsy, Gouri Shankar Bhattacharyya
Publikováno v:
Lung Cancer. 86:231-236
Objective Bavituximab is a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating and tumor-specific vascular targeting properties. Preclinical studies have shown activity against numerous solid tumors and at least an additive e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc96993962feaddefa1055e6021b4d2f
https://doi.org/10.1016/j.lungcan.2014.08.010
https://doi.org/10.1016/j.lungcan.2014.08.010
Autor:
Rajeev Patrick Das, Minish Mahendra Jain, Venkata Sathya Suresh Attili, Ashok K. Vaid, Chaitanya Kumar, Bharath Rangarajan, Bandana Sharan, Shyam Aggarwal, Mala Srivastava, P.P. Bapsy, Sundaram Subramanian
Publikováno v:
Cytotherapy. 16:234-244
Background aims A phase II clinical trial of an autologous dendritic cell (DC) formulation for the management of refractory solid malignant tumors was conducted across six sites in India with an objective to study safety and efficacy. Methods A total
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38624d37e3497a88084796829d3c250
https://doi.org/10.1016/j.jcyt.2013.11.013
https://doi.org/10.1016/j.jcyt.2013.11.013
Autor:
Alison Jones, Bella Kaufman, Sergei Tjulandin, Michaela Lehle, Michael R. Clemens, Ashok K. Vaid, John R. Mackey, Andrew M Wardley, A. Feyereislova, Michaela Jahn, Cedric Revil, P.P. Bapsy
Publikováno v:
Journal of Clinical Oncology. 27:5529-5537
PurposeTAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor–copositive metastatic breast cancer (MBC).Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b77547a86bdb29778dc8a8580fe2690c
https://doi.org/10.1200/jco.2008.20.6847
https://doi.org/10.1200/jco.2008.20.6847
Autor:
P.P. Bapsy, T.P. Sahoo
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 25:19-27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca96b0ff1163ae32e0d4bfb013655ac6
https://doi.org/10.1055/s-0041-1733070
https://doi.org/10.1055/s-0041-1733070
Autor:
Geetashree Mukherjee, Muniyappa Gayathri Devi, M. Padma, L. Appaji, Bandagadde S. Arunakumari, Prasanna Kumari, Siddhartha Biswas, P.P. Bapsy, T.S. Sundareshan, Rao Cr
Publikováno v:
Cancer Genetics and Cytogenetics. 141:14-19
Cytogenetic analysis of fine needle aspiration cultures was performed on 189 patients with non-Hodgkin lymphoma from South India. Successful karyotyping was possible in 97 patients (51.3%). Burkitt lymphoma constituted 56% of the cases studied follow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f96d5e5b5cae6767eca67e5a4078df66
https://doi.org/10.1016/s0165-4608(02)00648-9
https://doi.org/10.1016/s0165-4608(02)00648-9